Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Seagen Inc. SGEN

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:SGEN)

Fundamentals Snapshot (NDAQ:SGEN)

Current News (NDAQ:SGEN)

Seagen Statement on Outcome of Daiichi Sankyo Arbitration

Business Wire 7 days ago

Seagen Reports Second Quarter 2022 Financial Results

Business Wire July 28, 2022

Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

PR Newswire July 26, 2022

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

Business Wire July 26, 2022

Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022

Business Wire July 8, 2022

Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer

Business Wire July 2, 2022

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Business Wire June 6, 2022

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Business Wire June 6, 2022

ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma

Business Wire June 3, 2022

Bullboard Posts (NDAQ:SGEN)

Next SGEN

$APC Similar model. Took one great invention and licensed it out to a whack ton of partners. Massive company grew from this.  ...
Goldnboy1 - February 5, 2022

Why Seattle Genetics is holding strong

 This biotechnology company is primarily focused on developing and commercializing therapies targeted for the treatment of cancer...
DerdreeLove2019 - June 24, 2020

ixs - super antibody tech

In the same space as SGEN but miles cheaper - might be worth a look to some big pharma.
mouserman - May 8, 2008

RE: Has anyone heard anything about

I have just heard about this one from stockgumshoe.com - a site dedicated to sleuthing teaser ads. This one comes in a teaser ad for the...
mikeyr47 - March 5, 2008

Has anyone heard anything about

I guess some big people have put some big money in to this stock lately... Has anyone heard anything about it?
nigcar007 - February 17, 2008

Has anyone heard anything about

I guess some big people have put some big money in to this stock lately... Has anyone heard anything about it?
nigcar007 - February 17, 2008